www.helicobacterkorea.org

The 28th Annual Meeting of the Korean College of Helicobacter and Upper Gastrointestinal Research & the 3rd Seoul International Symposium on Helicobacter and Upper Gastrointestinal Diseases

SI-HUG 2020

Korean College of Helicobacter and Upper Gastrointestinal Research

July 17-18, 2020 CONRAD SEOUL, Korea

The 28th Annual Meeting of the Korean College of Helicobacter and Upper Gastrointestinal Research & the 3rd Seoul International Symposium on Helicobacter and Upper Gastrointestinal Diseases

154

PD-001

Propolis ethanol extract activity as anti-Helicobacter pylori on clarithromycin and metronidazole resistant strains

Yudith Annisa Ayu Rezkitha1,2,8, I Ketut Adnyana4, Yobella Priskila5, Ariel Panjaitan5, Elin Yulinah5, Neneng Ratnasari6, Ali Khomsan7, Ricky Indra Alfaray8,9, Kartika Afrida Fauzia8,9, Yoshio Yamaoka9, Muhammad Miftahussurur3,8 1Doctoral Program of Medical Science, Faculty of Medicine Universitas Airlangga, Surabaya, Jawa Timur, Indonesia, 2Faculty of Medicine, University Muhammadiyah of Surabaya, Surabaya, Jawa Timur, Indonesia, 3Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine-dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, Indonesia, 4School of Pharmacy, School of Pharmacy, Bandung Institute of Technology, Bandung, Jawa Barat, Indonesia, 5Department of Pharmaceutical Chemistry, School of Pharmacy, Bandung Institute of Technology, Bandung, Jawa Barat, Indonesia, 6Department of Internal Medicine, Faculty of Medicine, Gadjah Mada University-dr. Sardjito Hospital, Yogyakarta, Indonesia, 7Department of Community Nutrition, Bogor Agriculture University, Bogor, Indonesia, 8Institute of Tropical Disease, Universitas Airlangga, Surabaya, Jawa Timur, Indonesia, 9Department of Environmental And Preventive Medicine, Oita University Faculty of Medicine, Yufu, Oita, Japan

Purpose : Eradication of Helicobacter pylori infection still

become issue in Indonesia because of antimicrobial re-

sistance is still high, especially for metronidazole and

clarithromycin that is commonly used in the national

regiment therapy. Propolis extract is well known sub-

stance which has antimicrobial effect against some gram-

negative bacteria, but the effect against Helicobacter pylo-

ri remain unknown. The aim of this study was to know

the antimicrobial effect of Propolis extract against

Helicobacter pylori in clarithromycin and netronidazole

resistant strains.

Methods : Raw propolis from bee Trigona spp. obtained

from South Sulawesi, Indonesia was extracted by reflux

method using 70% ethanol, filtered and concentrated.

Anti-Helicobacter pylori effect of ethanol propolis extract

was tested on 10 types of Helicobacter pylori strains iso-

lated from dyspeptic patients. Microdilution method

and scratch method based on the results of the micro-

dilution test was used in determining the minimum in-

hibitory concentration (MIC) and minimum bactericidal

concentration (MBC) value of propolis extract used.

Combination effects were determined using the paper

tape method.

Results : Ethanol propolis extracts showed inhibition ac-

tivity at concentrations of 5% and 10% on all strains

Helicobacter pylori.  MIC and MBC values were in the

range of 1024 - 8192 μg/mL and  1024 - 16348 μg/mL,

respectively. Propolis extract concentration required to

obtain a bactericidal effect against Helicobacter pylori was

the same or eight-fold higher than the corresponding

value. The combination of propolis extract and metroni-

dazole or claritomycin showed an additive effect.

Conclusions : Propolis might be can become additional

treatment against Helicobacter pylori infection that resist-

ance for metronidazole and clarithromycin treatment.

Key words : Helicobacter pylori, Propolis, Clarithromycin;

Metronidazole

PD-002

Comparison of furazolidone versus clarithromycin for eradication of Helicobacter pylori infection: A randomized multicenter clinical trial

Pezhman Alavinejad1, Seyed Saeed Seiedian1, Kave Ebadi Borna2, Eskandar Hajiani1, Maryam Lajmirnia1, Saeed Hesam3 1Alimentary Tract Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khuzestan, Iran, Islamic Republic of, 2Gi Ward, Ahvaz Amir-almomenin Hospital, Ahvaz, Khuzestan, Iran, Islamic Republic of, 3Department of Biostatics And Epidemiology School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khuzestan, Iran, Islamic Republic of

Purpose : To evaluate efficacy of furazolidone versus clar-

ithromycin in quadruple therapy for eradication of

Helicobacter pylori (HP)

Methods : During a 6 months period, all of the cases  of

HP infection in 3 referral tertiary centers included

and randomly allocate to receive  either clarithromycin

or furazolidone base  quadruple regimen. For all of the

participants  pantoprazole continued for 4 more weeks,

They underwent urea breath test to prove eradication. 

Results : Overall 390 patients included (165 male (42%),

average age 44.2y).  They diagnosed as non-ulcer dys-

pepsia (311 cases), peptic ulcer disease (30 cases) and in-

testinal metaplasia (45 cases). The participants randomly

allocated to groups A & B to receive either clari-

thromycin or furazolidone.  In groups A and B, 80.9% &

82.1% of participants achieved eradication respectively

(P = 0.819). During study, there was not any major com-

plication but 3.1% of participants in each group re-

E-poster

155

ported minor side effects. In sub group analysis, the

eradication rate of clarithromycin among patients with

non-ulcer dyspepsia, PUD and intestinal metaplasia

were 80%, 100% & 55.6% respectively. These figures in

group B (furazolidone) were 80.7%, 100% & 85.7% re-

spectively (P = 0.906, 0 and 0.162; table 2). Overall, there

was no significant difference in success rate between clar-

ithromycin and furazolidone but in cases with intestinal

metaplasia, the positive results with furazolidone was

more (85.7% vs. 55.6%).

Conclusions : In areas with high rate of resistance to clar-

ithromycin, furazolidone could be a potential substitute

in HP eradication regimen and in cases with intestinal

metaplasia; furazolidone could be even more efficient.  

Key words : Furazolidone, Clarithromycin, Hp

Flow chart of study (ITT: intention to treat; PP: per pro-

tocol; PABC: pantoprazole, amoxicillin, bismuth, clari-

thromycin; PABF: pantoprazole, amoxicillin, bismuth,

furazolidone).

PD-003

Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia

Ayoung Lee1, Hyunsoo Chung1, Junshik Hong2, Youngil Koh2, Soo-Jeong Cho1, Ja Min Byun2, Sang Gyun Kim1, Inho Kim2 1Department of Internal Medicine And Liver Research Institute,, Seoul National University College of Medicine, Seoul, Korea, Republic of, 2Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of

Purpose : Helicobacter pylori (H. pylori) infection is on

the rise as a cause of ITP, and the results show that platelet

recovery can be achieved after successful eradication.

The aim of this study is to clarify the long-term effect of

H. pylori eradication monotherapy on the platelet count

recovery in patients with ITP.

Methods : This study evaluated the long-term effects of

H. pylori eradication monotherapy on platelet count re-

covery in patients with ITP. H. pylori eradication was an-

alyzed in 61 ITP patients. Patients who maintained a

complete response (CR) for more than six months were

classified as sustained responders (SR). 

Results : The prevalence of H. pylori infection was 54.3%

(75/138) and the success rate of eradication with

first-line therapy was 71.4% (35/49). Among the 61 pa-

tients, patients who achieved a complete response (CR)

at 2 months maintained a higher platelet counts there-

after (Figure 1). At 1 year after eradication, platelet count

increased 2.78 times in the eradicated group, 1.36 times

in the sustained infection group and 1.33 times in the no

infection group compared with baseline (P = 0.016). The

patients in the eradicated group and reached CR at 2

months after eradication showed SR in 77.8% (vs 14.3%

in NR, P = 0.010, Table 1).

Conclusions : In ITP patients with H. pylori infection,

the duration of CR in the eradicated group was longer

than sustained infection group, and obtaining CR at 2

months was associated with a sustained response.

Key words : Immune Thrombocytopenia, Helicobacter

pylori Eradication, Platelet Recovery

Figure 1. Trend of Platelet Counts during 5-Year Follow-Up

among Groups with H. pylori Infection Status

The 28th Annual Meeting of the Korean College of Helicobacter and Upper Gastrointestinal Research & the 3rd Seoul International Symposium on Helicobacter and Upper Gastrointestinal Diseases

156

Table 1. Baseline characteristics between sustained res-

ponder and non-sustained responder in eradicated

group

PD-004

Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: Follow-up for up to 15 years

Nayoung Kim, Yonghoon Choi, Cheol Min Shin, Dong Ho Lee Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

Purpose : Helicobacter pylori (HP) is known to play an

important role in the development of gastric cancer

(GC). The aim of this study was to analyze the effect of

HP eradication on the survival rate and cancer re-

currence in patients who underwent subtotal gas-

trectomy for GC.

Methods : A total of 1,379 patients diagnosed with gas-

tric adenocarcinoma who received surgical treatment at

the Seoul National University Bundang Hospital from

2003 to 2017 and tested positive for HP infection were

retrospectively analyzed. The overall and GC-related

survival according to HP eradication were compared;

other risk factors for GC-specific death and cancer re-

currence were analyzed, and propensity score matching

was performed.

Results : Statistically significant benefits of overall and

GC-specific survival were observed in the eradicated

group (n=779) compared to the non-eradicated group

(n=600) (all p<0.001), and these significant benefits

were maintained after propensity score matching (each

group n=525, all p<0.001). In Cox proportional hazards

univariate and multivariate analyses, age ≥60 years, final

cancer stage, and HP positivity were found to be in-

dependent risk factors for GC-specific death (age ≥60

years, adjusted hazard ratio [aHR] 1.74, p=0.014; cancer

stage II, aHR 5.94, p<0.001; cancer stage above III, aHR

17.35, p<0.001; HP positivity, aHR 3.79, p<0.001). In

addition, final cancer stage and HP positivity were in-

dependent risk factors for cancer recurrence (cancer

stage above III, aHR 6.62, p=0.004; HP positivity, aHR

3.89; p<0.001).

Conclusions : Our results suggest that treatment for HP

should be conducted more intensively in patients who

are surgically treated for GC, regardless of cancer stage.

Key words : Helicobacter pylori, Subtotal Gastrectomy,

Eradication

Jae Gyu Kim, M.D., Ph.D.

PresidentKorean College of Helicobacter and Upper Gastrointestinal Research

This is to certify that

SI-HUG 2020 Distinguished Poster Award

Has been selected as the awardee ofthe SI-HUG Distinguished Poster Award,

at the 28th Annual Meeting of the Korean College ofHelicobacter and Upper Gastrointestinal Research &

the 3rd Seoul International Symposium onHelicobacter and Upper Gastrointestinal Diseases,

held in Seoul, Korea.

July 17-18, 2020

Faculty of Medicine Universitas Airlangga, Indonesia

Yudith Annisa Ayu Rezkitha

Taiwan Fellowship Kotak Masuk x

辦事處

Kam, 17 Okt 00.43

kepada saya, erin.ichilin

Dear Bu Arin,

Kami ucapkan selamat, penelitian Anda mengenai "Enhancing Gender Fair Culture in Taiwan:

Opportunities and Challenges in Accessibility to Business Capital for Indonesian Migrant

Women" telah terpilih dalam 2019 Taiwan Fellowship.

Penelitian ini akan dimulai dari Januari -Juni 2020 (6 bulan) dan Anda akan mendapatkan

allowance fee sebesar NTD $50,000/bulan.

Terlampir adalah Guidelines mengenai Taiwan Fellowship, mohon dibaca terlebih dahulu. Dan

mohon dikonfirmasi kembali persetujuan mengikuti Taiwan Fellowship ini melalui email paling

lambat hari Senin (21 Oktober 2019) sebelum jam 10:00 pagi.

Thanks & Regards

Nita